XCHO Xenacare Holdings Inc. featured news, full reports, and detailed charts
Xenacare Holdings Inc. (XCHO/XCHO.OB) Wrap Up:
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. Its clinical products include XenaCor, which lowers serum cholesterol, C-reactive protein, and homocysteine levels designed to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. XenaCare’s clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including S...Xenacare Holdings Inc. (XCHO:OTC Bulletin Board Market)
Snapshot of Xenacare Holdings Inc. (XCHO)
|
OPEN
$0.10
|
PREVIOUS CLOSE
$0.10
|
|
|
DAY HIGH
$0.10
|
DAY LOW
$0.08
|
|
|
52 WEEK HIGH
06/16/09 - $0.32
|
52 WEEK LOW
08/6/09 - $0.01
|
|
|
MARKET CAP
6.0M
|
AVERAGE VOLUME 3 mo
284.9K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
65.7M
|
|
|
XCHO Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
XCHO Top Compensated Officers
Executives, Board Directors
Key developments for Xenacare Holdings Inc. (XCHO)
XenaCare Holdings Inc. has announced that the Chain Drug Marketing Association will begin inventorying Cobroxin for redistribution to its member pharmacies. The CDMA currently has over 6,000 independent pharmacy members throughout the United States.
Nutra Pharma Corporation has announced that it has successfully completed a licensing agreement that grants Xenacare Holdings Inc. ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements. Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm Inc., will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating repetitive stress, arthritis, and joint pain.
On 08/14/2009, Xenacare Holdings Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
XCHO Competitors
| Company | Last | Change | |
| No competitor information is available for XCHO. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | XCHO | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 38.6x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
XCHO |
||
XCHO transactions
| Type Date |
Target |
|
Private Placement
August 5, 2009 |
-- |